PUBLISHER: The Business Research Company | PRODUCT CODE: 1945504
PUBLISHER: The Business Research Company | PRODUCT CODE: 1945504
Mammalian cell banking is the organized procedure of producing, preserving, and storing well-characterized mammalian cell stocks under strict conditions, typically at very low temperatures, to ensure their long-term survival, genetic consistency, and functional performance. This method maintains the cells' uniformity, prevents contamination, and preserves their original traits over time, providing a reliable and standardized resource for future use.
The primary types of products in mammalian cell banking are master cell bank and working cell bank. A master cell bank (MCB) is a carefully prepared and extensively characterized collection of cells stored in multiple vials under controlled cryogenic conditions. It includes various cell types such as Chinese hamster ovary (CHO), baby hamster kidney (BHK), non-secreting 0 (NS0), YB2/0 and P2/0, human embryonic kidney 293 (HEK293) and derivatives, and HeLa cells. Storage methods include liquid nitrogen, controlled-rate freezing, and flash freezing. Master cell banks are used in drug development, vaccine production, gene therapy, and monoclonal antibody production, serving end users such as academic and research laboratories, biopharmaceutical companies, and contract research organizations (CROs).
Tariffs have influenced the mammalian cell banking market by raising costs for cryogenic equipment, storage systems, and specialized consumables sourced internationally. Biopharmaceutical production hubs in North America, Europe, and Asia-Pacific are most affected, particularly master and working cell bank segments. On the positive side, tariffs are driving domestic manufacturing investments, improved supply chain security, and regional cell banking infrastructure development.
The mammalian cell banking market research report is one of a series of new reports from The Business Research Company that provides mammalian cell banking market statistics, including mammalian cell banking industry global market size, regional shares, competitors with a mammalian cell banking market share, detailed mammalian cell banking market segments, market trends and opportunities, and any further data you may need to thrive in the mammalian cell banking industry. This mammalian cell banking market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The mammalian cell banking market size has grown rapidly in recent years. It will grow from $3.14 billion in 2025 to $3.5 billion in 2026 at a compound annual growth rate (CAGR) of 11.3%. The growth in the historic period can be attributed to monoclonal antibody development, vaccine manufacturing growth, regulatory quality requirements, academic research expansion, biologics commercialization.
The mammalian cell banking market size is expected to see rapid growth in the next few years. It will grow to $5.31 billion in 2030 at a compound annual growth rate (CAGR) of 11.0%. The growth in the forecast period can be attributed to gene therapy advancements, personalized medicine growth, biosimilar development, cell-based therapy pipelines, long-term cell traceability needs. Major trends in the forecast period include standardization of cell line preservation, growth of biopharmaceutical pipelines, expansion of CGMP-compliant cell banks, increased focus on genetic stability, rising outsourcing to specialized facilities.
The growing demand for cell-based therapies is expected to significantly drive the expansion of the mammalian cell banking market. Cell-based therapies involve advanced treatments using living, often modified or engineered, cells to repair, replace, or regenerate damaged tissues and organs, offering targeted solutions for various diseases. As chronic and rare diseases become more prevalent, there is an increasing need for more effective and precise treatments. Mammalian cell banking plays a key role in supporting these therapies by providing a consistent, high-quality cell source, ensuring safety, scalability, and reliability in the development and production of regenerative treatments. For example, the American Society of Gene and Cell Therapy reported in April 2024 that the number of therapies in clinical pipelines has grown, with Phase I trials showing the strongest growth of 11% since late 2022. This surge in demand for cell-based therapies is therefore fueling the growth of the mammalian cell banking market.
Companies in the mammalian cell banking market are advancing the field by developing innovative stable cell line systems that improve cell line productivity, ensure long-term genetic stability, and streamline biopharmaceutical manufacturing. Stable cell line systems are engineered mammalian cells that can consistently produce specific proteins or therapeutic molecules across generations with high genetic stability. For example, WuXi Biologics, a biopharmaceutical company based in China, introduced the WuXia293 Stable platform in August 2024. This HEK293-based stable cell line system is designed for the development and production of challenging biologic molecules. By using proprietary cell line development technology, the platform ensures stable expression, consistent quality, and scalable production, overcoming challenges typically seen with traditional CHO cell systems, such as low yields and compromised quality. The WuXia293 Stable platform provides higher protein yields, better human-like glycosylation, and more efficient production for clinical and commercial use.
In April 2025, Sartorius, a Germany-based life sciences technology provider, formed a strategic CDMO collaboration with Mabion S.A. to support comprehensive biopharmaceutical development using mammalian cell systems. This partnership enables Sartorius to enhance its capabilities in mammalian cell banking by combining advanced cell line development, upstream process optimization, and proprietary cell culture media with Mabion's GMP-compliant process development, scale-up, and large-scale biologics manufacturing. Mabion is a Poland-based biopharmaceutical CDMO focused on mammalian cell culture-based protein production and GMP manufacturing of both drug substances and drug products.
Major companies operating in the mammalian cell banking market are Merck KGaA, Thermo Fisher Scientific Inc., Lonza Group AG, Eurofins Scientific SE, Charles River Laboratories International Inc., Catalent Inc., Sartorius Stedim Biotech S A, Samsung Biologics Co Ltd, CMIC Holdings Co Ltd, WuXi Biologics Inc., Evotec SE, AGC Biologics Inc., GenScript ProBio Co Ltd, Syngene International Limited, KBI Biopharma Inc., Rentschler Biopharma SE, Polpharma Biologics S A, Abzena plc, 53Biologics, Cellistic, GBI Biomanufacturing, ABL Inc, OmniaBio, uBriGene Biosciences
North America was the largest region in the mammalian cell banking market in 2025. The regions covered in the mammalian cell banking market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the mammalian cell banking market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The mammalian cell banking market consists of sales of cryopreservation media, cell culture reagents, storage vials, cryogenic storage equipment, and quality control kits. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Mammalian Cell Banking Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses mammalian cell banking market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for mammalian cell banking ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The mammalian cell banking market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.